Protection of Fecal Microbiota Transplantation in a Mouse Model of Multiple Sclerosis
Open accessThe DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.
Abstract
Given the growing evidence of a link between gut microbiota (GM) dysbiosis and multiple sclerosis (MS), fecal microbiota transplantation (FMT), aimed at rebuilding GM, has been proposed as a new therapeutic approach to MS treatment. To evaluate the viability of FMT for MS treatment and its impact on MS pathology, we tested FMT in mice with experimental autoimmune encephalomyelitis (EAE), a mouse model of MS. We provide evidence that FMT can rectify altered GM to some extent with a therapeutic effect on EAE. We also found that FMT led to reduced activation of microglia and astrocytes and conferred protection on the blood-brain barrier (BBB), myelin, and axons in EAE. Taken together, our data suggest that FMT, as a GM-based therapy, has the potential to be an effective treatment for MS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
From Dietary Fiber to Host Physiology: Short-Chain Fatty Acids as Key Bacterial Metabolites
Koh, A., De Vadder, F., Kovatcheva-Datchary, P., & Bäckhed, F. (2016) · Cell · doi:10.1016/j.cell.2016.05.041 · Cited by 7,070
Role of the microbiota in immunity and inflammation.
Belkaid, Y., & Hand, T. W. (2014) · Cell · doi:10.1016/j.cell.2014.03.011 · Cited by 5,385
den Besten, G., van Eunen, K., Groen, A. K., Venema, K., Reijngoud, D.-J., & Bakker, B. M. (2013) · Journal of Lipid Research · doi:10.1194/jlr.r036012 · Cited by 5,048
Host microbiota constantly control maturation and function of microglia in the CNS
Erny, D., Hrabě de Angelis, A. L., Jaitin, D., Wieghofer, P., Staszewski, O., David, E., Keren-Shaul, H., Mahlakoiv, T., Jakobshagen, K., Buch, T., et al. (2015) · Nature Neuroscience · doi:10.1038/nn.4030 · Cited by 3,569
Vrieze, A., Van Nood, E., Holleman, F., Salojärvi, J., Kootte, R. S., Bartelsman, J. F. W. M., Dallinga–Thie, G. M., Ackermans, M. T., Serlie, M. J., Oozeer, R., et al. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.06.031 · Cited by 2,913
Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis
The International Multiple Sclerosis Genetics Consortium & The Wellcome Trust Case Control Consortium 2 (2011) · Nature · doi:10.1038/nature10251 · Cited by 2,697
The gut microbiota influences blood-brain barrier permeability in mice
Braniste, V., Al-Asmakh, M., Kowal, C., Anuar, F., Abbaspour, A., Tóth, M., Korecka, A., Bakocevic, N., Ng, L. G., Kundu, P., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3009759 · Cited by 2,530
Role of the gut microbiota in immunity and inflammatory disease
Kamada, N., Seo, S.-U., Chen, G. Y., & Núñez, G. (2013) · Nature reviews. Immunology · doi:10.1038/nri3430 · Cited by 2,256
Moayyedi, P., Surette, M. G., Kim, P. T., Libertucci, J., Wolfe, M., Onischi, C., Armstrong, D., Marshall, J. K., Kassam, Z., Reinisch, W., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.001 · Cited by 1,499 · cited 1×
“So far, FMT has been tested in treating a variety of conditions including Clostridium difficile infection [42, 57], active ulcerative colitis [58], high-fat diet-induced steatohepatitis [59], metabolic syndrome [60], and CNS diseases such as epilepsy [21] and autism spectrum disorder [61].”
BackgroundKang, D.-W., Adams, J. B., Gregory, A. C., Borody, T., Chittick, L., Fasano, A., Khoruts, A., Geis, E., Maldonado, J., McDonough-Means, S., et al. (2017) · Microbiome · doi:10.1186/s40168-016-0225-7 · Cited by 1,391
Cited by
The role of gut dysbiosis in Parkinson’s disease: mechanistic insights and therapeutic options
Wang, Q., Luo, Y., Ray Chaudhuri, K., Reynolds, R., Tan, E.-K., & Pettersson, S. (2021) · Brain · doi:10.1093/brain/awab156 · Cited by 281
Parkinson’s disease and gut microbiota: from clinical to mechanistic and therapeutic studies
Zhang, X., Tang, B., & Guo, J. (2023) · Translational Neurodegeneration · doi:10.1186/s40035-023-00392-8 · Cited by 187
“It has been proven that patients with different neurological diseases, including PD, benefit from FMT therapy [298–300].”
BackgroundCheca-Ros, A., Jeréz-Calero, A., Molina-Carballo, A., Campoy, C., & Muñoz-Hoyos, A. (2021) · Nutrients · doi:10.3390/nu13010249 · Cited by 164
“In a mouse model of multiple sclerosis, fecal microbiota transplantation rebuilt the gut microbiome and provided therapeutic benefits by conferring protection on the myelin, with additional effects on the blood–brain barrier and the populations of astrocytes [63].”
BackgroundGheorghe, C. E., Ritz, N. L., Martin, J. A., Wardill, H. R., Cryan, J. F., & Clarke, G. (2021) · Gut Microbes · doi:10.1080/19490976.2021.1941711 · Cited by 148
Targeting the gut to treat multiple sclerosis
Ghezzi, L., Cantoni, C., Pinget, G. V., Zhou, Y., & Piccio, L. M. (2021) · Journal of Clinical Investigation · doi:10.1172/jci143774 · Cited by 122
Gut Dysbiosis and Fecal Microbiota Transplantation in Autoimmune Diseases
Belvončíková, P., Marônek, M., & Gardlík, R. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231810729 · Cited by 131
Du, D., Tang, W., Zhou, C., Sun, X., Wei, Z., Zhong, J., & Huang, Z. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/5816837 · Cited by 111
“showed that FMT can improve the neurological function in the model of multiple sclerosis, Parkinson’s disease, and stroke [9, 17, 53, 54].”
BackgroundSelf-citationParodi, B., & de Rosbo, N. K. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.718220 · Cited by 125
Fecal Microbiota Transplantation: A New Therapeutic Attempt from the Gut to the Brain
Xu, H.-M., Huang, H.-L., Zhou, Y.-L., Zhao, H.-L., Xu, J., Shou, D.-W., Liu, Y.-D., Zhou, Y.-J., & Nie, Y.-Q. (2021) · Gastroenterology Research and Practice · doi:10.1155/2021/6699268 · Cited by 96
“similarly showed that FMT from healthy mice alleviated the symptoms in EAE mice by reducing activity of microglia and astrocytes and restoring the blood-brain barrier integrity and axonal myelination [111].”
BackgroundFecal microbiota transplantation: Emerging applications in autoimmune diseases
Yang, R., Chen, Z., & Cai, J. (2023) · Journal of Autoimmunity · doi:10.1016/j.jaut.2023.103038 · Cited by 111
Matheson, J.-A. T., & Holsinger, R. M. D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021001 · Cited by 102
“These changes were associated with reductions in demyelination as well as astrocytic and microglial activation [72].”
Alcohol as friend or foe in autoimmune diseases: a role for gut microbiome?
Caslin, B., Mohler, K., Thiagarajan, S., & Melamed, E. (2021) · Gut Microbes · doi:10.1080/19490976.2021.1916278 · Cited by 94
Hygiene hypothesis and autoimmune diseases: A narrative review of clinical evidences and mechanisms
Murdaca, G., Greco, M., Borro, M., & Gangemi, S. (2021) · Autoimmunity Reviews · doi:10.1016/j.autrev.2021.102845 · Cited by 100
The Gut Microbiome as a Regulator of the Neuroimmune Landscape
Yu, L. W., Agirman, G., & Hsiao, E. Y. (2022) · Annual Review of Immunology · doi:10.1146/annurev-immunol-101320-014237 · Cited by 75
Gut Microbiota Regulate Astrocytic Functions in the Brain: Possible Therapeutic Consequences
Zhao, Y.-F., Wei, D., & Tang, Y. (2021) · Current Neuropharmacology · doi:10.2174/1570159x19666210215123239 · Cited by 66
“The studies mentioned above have evaluated how, through pharmacological and nonpharmacological means, gut microbiota may regulate astrocyte function [46, 47, 50, 150, 151].”
BackgroundBioque, M., González-Rodríguez, A., García‐Rizo, C., Cobo, J., Monreal, J. A., Usall, J., Soria, V., & Labad, J. (2020) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2020.110130 · Cited by 64
Ertürk-Hasdemir, D., Ochoa‐Repáraz, J., Kasper, D. L., & Kasper, L. H. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.662807 · Cited by 59
Feng, R., Zhu, Q., Wang, A., Wang, H., Wang, J., Chen, P., Zhang, R., Liang, D., Teng, J., Ma, M., et al. (2024) · BMC Medicine · doi:10.1186/s12916-024-03781-6 · Cited by 53
Hashemi, B., Abdollahi, M., Abbaspour‐Aghdam, S., Hazrati, A., Malekpour, K., Meshgi, S., Kafil, H. S., Ghazi, F., Yousefi, M., Roshangar, L., et al. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.114195 · Cited by 52
The Brain–Gut–Bone Axis in Neurodegenerative Diseases: Insights, Challenges, and Future Prospects
Li, R., Miao, Z., Liu, Y., Chen, X., Wang, H., Su, J., & Chen, J. (2024) · Advanced Science · doi:10.1002/advs.202307971 · Cited by 64
The Evolving Landscape of Fecal Microbial Transplantation
Shao, T., Hsu, R., Hacein-Bey, C., Zhang, W., Gao, L., Kurth, M. J., Zhao, H., Shuai, Z., & Leung, P. S. C. (2023) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-023-08958-0 · Cited by 48
Targeting gut microbiota: new therapeutic opportunities in multiple sclerosis
Kujawa, D., Łaczmański, Ł., Budrewicz, S. P., Pokryszko‐Dragan, A., & Podbielska, M. (2023) · Gut Microbes · doi:10.1080/19490976.2023.2274126 · Cited by 47
Jing, Y., Bai, F., Wang, L., Yang, D., Yan, Y., Wang, Q., Zhu, Y., Yu, Y., & Chen, Z. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.00177-22 · Cited by 37
Kumar, N., Sahoo, N. K., Mehan, S., & verma, B. (2023) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2023.104547 · Cited by 46
Davis, B. T., Chen, Z., Islam, M. B. A. R., Timken, M. E., Procissi, D., & Schwulst, S. J. (2022) · Shock · doi:10.1097/shk.0000000000001934 · Cited by 38
“This is corroborated by our own data in the current study as well as evidence in the literature showing that FMT modulates the recruitment and activation of astrocytes and microglia in mouse models of Alzheimer’s (Alz) and multiple sclerosis (MS) (28, 29).”
ResultLiu, X., Liu, M., Zhao, M., Li, P., Gao, C., Fan, X., Cai, G., Lu, Q., & Chen, X. (2023) · Journal of Autoimmunity · doi:10.1016/j.jaut.2023.103109 · Cited by 43
Current Status and Future Therapeutic Options for Fecal Microbiota Transplantation
Ткач, С. М., Dorofeyev, A., Kuzenko, I., Boyko, N., Falalyeyeva, T. M., Boccuto, L., Scarpellini, E., Kobyliak, N. M., & Abenavoli, L. (2022) · Medicina · doi:10.3390/medicina58010084 · Cited by 41
Wang, S., Chen, H., Wen, X., Mu, J., Sun, M., Song, X., Liu, B., Chen, J., & Fan, X. (2021) · Journal of Immunology Research · doi:10.1155/2021/4400428 · Cited by 37
“our study, a previous study found that FMT has a certain therapeutic effect on the EAE model [19].”
ResultMultiple Sclerosis and Microbiome
Preiningerova, J. L., Zakostelska, Z. J., Srinivasan, A., Tichá, V., Kovářová, I., Kleinová, P., Tlaskalová-Hogenová, H., & Havrdová, E. (2022) · Biomolecules · doi:10.3390/biom12030433 · Cited by 49
“In EAE, FMT had a therapeutic effect delaying the onset of disease and reducing clinical severity [59].”
BackgroundNowland, T. L., Kirkwood, R. N., & Pluske, J. R. (2021) · animal · doi:10.1016/j.animal.2021.100368 · Cited by 60
Uceda, S., Echeverry‐Alzate, V., Reiriz, M., Miguel, E. M., Pérez-Curiel, A., Gómez-Senent, S., & Beltrán-Velasco, A. I. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241713294 · Cited by 39
ILC3, a Central Innate Immune Component of the Gut-Brain Axis in Multiple Sclerosis
Miljković, D. M., Jevtić, B., Stojanović, I., & Dimitrijević, M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.657622 · Cited by 31
“The efficiency of fecal microbiota transfer (FMT) has been demonstrated in EAE (104, 105).”
BackgroundMirashrafi, S., Taghanaki, S. Z. H., Sarlak, F., Moravejolahkami, A. R., Kermani, M. A. H., & Haratian, M. (2021) · International Journal of Clinical Practice · doi:10.1111/ijcp.14724 · Cited by 34
Fecal Microbiota Transplantation: A Microbiome Modulation Technique for Alzheimer’s Disease
Nandwana, V., & Debbarma, S. (2021) · Cureus · doi:10.7759/cureus.16503 · Cited by 33
“They observed that FMT can correct altered gut microbiota and confer protection on the BBB, myelin, and axons, as well as can reduce the activation of microglia and astrocytes, thus suggesting the role of FMT as a potentially effective treatment for MS [53].”
BackgroundMelamed, E., Palmer, J. L., & Fonken, C. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.1019877 · Cited by 29
Eslami, M., Adampour, Z., Dowlat, B. F., Yaghmayee, S., Tabaei, F. M., Oksenych, V., & Naderian, R. (2025) · Biomedicines · doi:10.3390/biomedicines13040915 · Cited by 31
Ahmed, L. A., & Al‐Massri, K. F. (2022) · Current Molecular Pharmacology · doi:10.2174/1874467215666220222105004 · Cited by 26
Yadav, S., & Raj, R. G. (2025) · Neuroscience · doi:10.1016/j.neuroscience.2025.07.003 · Cited by 28
Lynch, C. M. K., Nagpal, J. K., Clarke, G. A., & Cryan, J. F. (2021) · Current Opinion in Physiology · doi:10.1016/j.cophys.2021.100468 · Cited by 27
Gut Dysbiosis and Blood-Brain Barrier Alteration in Hepatic Encephalopathy: From Gut to Brain
Shahbazi, A., Sepehrinezhad, A., Vahdani, E., Jamali, R., Ghasempour, M., Massoudian, S., Negah, S. S., & Larsen, F. S. (2023) · Biomedicines · doi:10.3390/biomedicines11051272 · Cited by 27
“Experimental autoimmune encephalomyelitis mouse model of multiple sclerosis FMT (from control mice) Decreased extravasation of Evans blue, increased protein expression of occludin-5 in the spinal cord, and reduced astrocyte reactivity, as well as decreased microglial activation in brain tissue [196]”
BackgroundZißler, J., Rothhammer, V., & Linnerbauer, M. (2024) · Cells · doi:10.3390/cells13060497 · Cited by 25
“In EAE models, FMT promotes a health-promoting bacterial composition, accompanied by strengthened and functional BBB integrity, reduced demyelination, and axonal loss [212].”
BackgroundGut microbiota in multiple sclerosis and animal models
Schumacher, S. M., Doyle, W. J., Hill, K., & Ochoa‐Repáraz, J. (2025) · The FEBS Journal · doi:10.1111/febs.17161 · Cited by 21
“FMT has increased interest as a potential therapy in MS due to the altered gut microbiota [159 – 161].”
New therapeutic avenues in multiple sclerosis: Is there a place for gut microbiota-based treatments?
Campagnoli, L. I. M., Marchesi, N., Varesi, A., Morozzi, M., Mascione, L., Ricevuti, G., Esposito, C., Galeotti, N., & Pascale, A. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107456 · Cited by 25
The role of the gut microbiota and fecal microbiota transplantation in neuroimmune diseases
Wu, N., Li, X., Ma, H., Zhang, X., Liu, B., Yuan, W., Zheng, Q., & Fan, X. (2023) · Frontiers in Neurology · doi:10.3389/fneur.2023.1108738 · Cited by 28
“These results suggest that FMT can alter the structure of gut microbiota in EAE to a certain extent.”
ResultInfluentialNemati, M. H., Yazdanpanah, E., Kazemi, R., Orooji, N., Dadfar, S., Oksenych, V., & Haghmorad, D. (2025) · Biology · doi:10.3390/biology14040435 · Cited by 28
“In MS experimental models, FMT from healthy mice to immunized mice altered the gut microbiota composition, reducing EAE symptom intensity, neurodegenerative marker expression, and pathological symptoms [110].”
The Role of Gut Microbiota in Blood–Brain Barrier Disruption after Stroke
Zeng, M., Peng, M., Liang, J., & Sun, H. (2023) · Molecular Neurobiology · doi:10.1007/s12035-023-03512-7 · Cited by 19
“…factor for early recovery in patients with IS Xu et al. [121] microbiota transplantation (FMT) from mice helps prevent BBB damage in experimental autoimmune encephalomyelitis (EAE) by increasing claudin-5 expression and attenuating the activation of microglia and astrocytes caused by EAE [142].”
More than just a number: the gut microbiota and brain function across the extremes of life
Nuzum, N. D., Deady, C., Kittel‐Schneider, S., Cryan, J. F., O’Mahony, S. M., & Clarke, G. A. (2024) · Gut Microbes · doi:10.1080/19490976.2024.2418988 · Cited by 25
“254 FMT also led to reduced activation of microglia and astrocytes while conferring some protection on the BBB, myelin and axons in the MS mice models.”
The role of Fecal Microbiota Transplantation (FMT) in treating patients with multiple sclerosis
Zhanel, G. G., Keynan, R., Keynan, Y., & Karlowsky, J. A. (2023) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2023.2250919 · Cited by 20
“The FMT group was administered 200 μl per mouse of fresh fecal supernatant daily for 42 consecutive days post-immunization while the EAE group received a fecal supernatant which was replaced with sterile saline [23].”
BackgroundMethodResultInfluentialLi, Y., Zhang, T., Sun, J., & Liu, N. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.899845 · Cited by 20
“…diseases, such as IBD, IBS (Cui et al., 2021), multiple sclerosis (Engen et al., 2020; Li et al., 2020), hepatic encephalopathy (Kao et al., 2016; Madsen et al., 2021), cancer (Chen et al., 2019; Kaźmierczak-Siedlecka et al., 2020; Zhu H. et al., 2020) and metabolic syndrome (Yu et al., 2020).”
BackgroundFaecal Microbiota Transplantation Alleviates Ferroptosis after Ischaemic Stroke
Wei, J., Wang, G., Lai, M., Zhang, Y., Li, F., Wang, Y., & Tan, Y. (2024) · Neuroscience · doi:10.1016/j.neuroscience.2024.01.021 · Cited by 19
“In addition, FMT can restore the changes in the gut microbiota caused by stroke, reduce the neuroinflam-67 matory response, diminish the permeability of the blood– brain barrier, and exert neuroprotective effects (Braniste et al., 2014; Singh et al., 2016; Spychala et al., 2018; Lee et al., 2020).”
BackgroundHost gut resistome in Gulf War chronic multisymptom illness correlates with persistent inflammation
Bose, D., Chatterjee, S., Older, E. A., Seth, R. K., Janulewicz, P. A., Saha, P., Mondal, A., Carlson, J. M., Decho, A. W., Sullivan, K. A., et al. (2022) · Communications Biology · doi:10.1038/s42003-022-03494-7 · Cited by 19
The role of the microbiome on immune homeostasis of the host nervous system
Zhao, S., Fu, D., Lin, Y., Sun, X., Wang, X., Wu, X., & Zhang, X. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1609960 · Cited by 16
Multiple sclerosis and the microbiota
Engelenburg, H. J., Lucassen, P. J., Sarafian, J. T., Parker, W., & Laman, J. D. (2022) · Evolution Medicine and Public Health · doi:10.1093/emph/eoac009 · Cited by 15
“These fecal transplant-induced improvements in disease progression appeared to be mediated by decreased immune system activation in the brain as well as by increased protection of the nervous system from damage [19].”
BackgroundMaturation, Morphology, and Function: The Decisive Role of Intestinal Flora on Microglia: A Review
Liu, L., Tong, F., Li, H., Bin, Y., Ding, P., Peng, L., Liu, Z., & Dong, X. (2023) · Journal of Integrative Neuroscience · doi:10.31083/j.jin2203070 · Cited by 14
“Further, transplantation of fecal from healthy mice into EAE mice modulates the gut microbiota of EAE mouse model, improves the severity of EAE by alleviating blood-brain barrier (BBB) leakage and decreasing microglia activation [78].”
BackgroundSelf-citationXu, D., Ren, L., Zhang, W., Wu, S., Yu, M., He, X., & Wei, Z. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e33214 · Cited by 14
“In addition, Li et al.[20] found that FMT treatment improved EAE symptoms and reduced intestinal A. muciniphila levels in mice.”
BackgroundMethodResultInfluentialVogrig, A., Dentoni, M., Florean, I., Cellante, G., Domenis, R., Iacono, D., Pelizzari, G., Rossi, S., Damato, V., Fabris, M., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1548897 · Cited by 23
Dong, J., Xie, T., Shi, C., Feng, G., Zhang, H., Xu, Z., & Dong, L. (2025) · Journal of Inflammation Research · doi:10.2147/jir.s543912 · Cited by 13
“248 For example, germ-free mice receiving FMT from Parkinson’s disease patients developed motor deficits, whereas healthy donor FMT reduced neuroinflammation and TLR/TNF-α signaling in Parkinson’s disease mice, demonstrating a neuroprotective effect.”
The Microbiome–Neurodegeneration Interface: Mechanisms, Evidence, and Future Directions
Böckels, L., Alexa, D., Antal, D. C., Gațcan, C., Alecu, C., Kacani, K., Cretu, R. A., Piseru, E.-A., Bîlcu, R. V., & Cuciureanu, D. I. (2026) · Cells · doi:10.3390/cells15020135 · Cited by 13
Overview of the Gut Microbiome
Blackmer‐Raynolds, L., & Sampson, T. R. (2023) · Seminars in Neurology · doi:10.1055/s-0043-1771463 · Cited by 12
Pyroptosis the Emerging Link Between Gut Microbiota and Multiple Sclerosis
Fan, H., Shen, R., Yan, J., Bai, Y., Fu, Q., Shi, X., Du, G., & Wang, D. (2024) · Drug Design Development and Therapy · doi:10.2147/dddt.s489454 · Cited by 12
Kashyap, Y., & Wang, Z. J. (2023) · Pain · doi:10.1097/j.pain.0000000000003034 · Cited by 11
Ahmadi, S., Hasani, A., Khabbaz, A., Poortahmasebi, V., Hosseini, S., Yasdchi, M., Mehdizadehfar, E., Mousavi, Z. B., Hasani, R., Nabizadeh, E., et al. (2024) · Biogerontology · doi:10.1007/s10522-024-10136-4 · Cited by 13
“In other study, FMT of naïve mice into immunized mice decreased microglia and astrocyte activation, BBB (blood–brain barrier) leakage, demyelination, and axonal loss in EAE (Li et al. 2020) (Supplementary Table 3–3).”
Wang, Y., Chen, Y., Xiao, Z., Shi, Y., Fu, C., & Cao, Y. (2025) · Renal Failure · doi:10.1080/0886022x.2025.2480749 · Cited by 11
“Many studies have shown that FMT is beneficial for treating diseases associated with dysregulated gut microbiota, including obesity, type 2 diabetes, multiple sclerosis, and Alzheimer’s disease [17,27,28,29].”
Pawlowski, K. D., David, B. T., & Fessler, R. G. (2022) · Journal of Neurotrauma · doi:10.1089/neu.2022.0264 · Cited by 10
“12 FMT has been shown to be beneficial in numerous CNS diseases such as ischemic stroke, 79 Parkinson’s disease, 80,81 Alzheimer’s disease, 82 multiple sclerosis, 83 and more recently, SCI.”
Sharifa, M., Ghosh, T., Daher, O. A., Bhusal, P., Alaameri, Y. A., Naz, J., Ekhator, C., Bellegarde, S. B., Bisharat, P., Vaghani, V., et al. (2023) · Cureus · doi:10.7759/cureus.47058 · Cited by 22
“Potential advantages include decreased microglia and astrocyte activation, enhanced blood brain barrier (BBB) integrity, and clinical stability, according to studies in EAE models and a case study involving a patient with MS [67,68].”
BackgroundCen, Q., Cui, Y., Jin, J., Feng, J., Xin, Y., Zhang, Z., Li, J., Wang, J., & Zhang, A. (2025) · Gut Microbes · doi:10.1080/19490976.2025.2576657 · Cited by 9
“261 Moreover, FMT has demonstrated potential therapeutic value in MS patients.”
Relationship Between Multiple Sclerosis, Gut Dysbiosis, and Inflammation
Jank, L., & Bhargava, P. (2023) · Neurologic Clinics · doi:10.1016/j.ncl.2023.07.005 · Cited by 9
Pisoni, L., Donini, L., Gagni, P., Pennuto, M., Ratti, A., Verde, F., Ticozzi, N., Mandrioli, J., Calvo, A., & Basso, M. (2025) · Cells · doi:10.3390/cells14110848 · Cited by 8
“…animal models of MS, fecal microbiota transplantation (FMT) is associated with a decrease in axonal damage markers (e.g., myelin binding protein and neurofilament light polypeptide (NFL)), intact myelin sheaths in the thoracic spinal cord, and a reduction in the number of activated microglia [61].”
Deciphering the microbial map and its implications in the therapeutics of neurodegenerative disorder
Vashishth, S., Ambasta, R. K., & Kumar, P. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102466 · Cited by 9
Haindl, R., Totzauer, L., & Kulozik, U. (2022) · Microbial Biotechnology · doi:10.1111/1751-7915.14007 · Cited by 7
“, 2020) or multiple sclerosis (Borody et al., 2011; Li et al., 2020) have been reported.”
BackgroundOlejnik, P., Buczma, K., Cudnoch‐Jędrzejewska, A., & Kasarełło, K. (2024) · Immunologic Research · doi:10.1007/s12026-024-09471-y · Cited by 9
“In addition, FMT administration was associated with a reduction in axonal and myelin damage and suppression of the glial inflammatory response in mice with induced EAE [90].”
Moghadam, M. T., Ramírez‐Coronel, A. A., Darijani, S., Akbarizadeh, M. R., Naderifar, M., Soltaninejad, S., Shahbazi, S., Dousari, A. S., Mojtahedi, A., & Akhavan‐Sigari, R. (2023) · Current Alzheimer Research · doi:10.2174/1567205020666230718160914 · Cited by 7
Su, S., Chen, M., Lu, D., Wu, Y.-F., Huang, X.-S., & Zhang, L. (2025) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2025.110122 · Cited by 5
The influence of aging and the microbiome in multiple sclerosis and other neurologic diseases
Fettig, N. M., Pu, A., Osborne, L. C., & Gommerman, J. L. (2024) · Immunological Reviews · doi:10.1111/imr.13361 · Cited by 7
“159-161 Furthermore, the MS microbiome has been shown to be pathogenic not only in EAE, 90,91 but also in other demyelination models.”
InfluentialLi, Q., Wang, G., Zhao, J., Chen, W., & Tian, P. (2025) · Microbiological Research · doi:10.1016/j.micres.2025.128286 · Cited by 7
Microglia sensing of peripheral signals that bridge the brain and body
Young, C. E., & Samuel, M. A. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00905-1 · Cited by 9
“Conversely, microbiome alteration via fecal microbiota transfer did improve outcomes in a mouse MS model [96].”
Cell‐based experimental strategies for myelin repair in multiple sclerosis
Borda, M., Aquino, J. B., & Mazzone, G. L. (2022) · Journal of Neuroscience Research · doi:10.1002/jnr.25129 · Cited by 4
“Consistently, fecal microbiota transplantation into a EAE model led to a reduction in microglia and astroglia activation, prevented brain– blood barrier leakage and conferred protection to myelin and axons (Li et al., 2020).”
BackgroundLadakis, D. C., & Bhargava, P. (2023) · CNS Drugs · doi:10.1007/s40263-023-00986-w · Cited by 6
“[93] transferred either fecal microbiota from healthy mice or normal saline to EAE-induced mice and found that mice that received FMT had less severe and slower progressive disease.”
BackgroundZhang, Y., Chen, L., Jin, J., Xin, Y., Wang, J., & Zhang, A. (2025) · Experimental Neurology · doi:10.1016/j.expneurol.2025.115631 · Cited by 5
Prospects for microbiome modulation in autoimmune diseases: a literature review
Peshkova, M., Korneev, A. A., Игоревна, К. П., Kosheleva, N. V., & Timashev, P. S. (2024) · Sechenov Medical Journal · doi:10.47093/2218-7332.2024.15.1.4-19 · Cited by 3
Tabatabaeizadeh, S., & Tafazoli, N. (2025) · International Journal of Clinical Practice · doi:10.1155/ijcp/3754973 · Cited by 2
“Tis difference with our results may be due to the main role of infammatory processes in patients with MS. Te results of our meta-analysis are similar to previous RCTs that have shown probiotics improve BDI scores [14–16].”
Ткач, С. М., Dorofeyev, A., Kuzenko, I., Boyko, N., Falalyeyeva, T. M., & Kobyliak, N. M. (2023) · Advances in predictive, preventive and personalised medicine · doi:10.1007/978-3-031-19564-8_10 · Cited by 3
Dong, Z., He, Y., Yin, T., Xu, K., Liu, X., Han, H., Song, L., Ding, Z., Li, X., & Su, Y. (2026) · Molecular Neurobiology · doi:10.1007/s12035-025-05566-1 · Cited by 1
“Notably, microbiota-targeted therapies conferred comprehensive neuroprotection by mitigating glial activation, preserving BBB integrity, and maintaining myelin and axonal structure [36].”
The relationship between intestinal dysbiosis and multiple sclerosis
", Sîrbu, C. A., Dumitru, R. M., Vasile, M., Ștefani, C., Ranetti, A.-E., Sirbu, A. M., Axelerad, A. D., & Ștefan, I. (2022) · Romanian Journal of Military Medicine · doi:10.55453/rjmm.2022.125.1.11 · Cited by 1
Reveles, K. R., Hickmott, A. J., Strey, K. A., Mustoe, A. C., Arroyo, J. P., Power, M. L., Ridenhour, B. J., Amato, K. R., & Ross, C. N. (2024) · Microorganisms · doi:10.3390/microorganisms12050852 · Cited by 4
Liu, N., Zhang, T., Sun, J., Fu, J.-H., & Li, H. (2021) · medRxiv · doi:10.1101/2021.11.18.21266556
Self-citationRen, L., Xu, D., Zhang, W., Wu, S., Yu, M., He, X., & Wei, Z. (2023) · SSRN Electronic Journal · doi:10.2139/ssrn.4530808
Lu, Q., & Xin, Y. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-23947-2.00008-4
The impact of gut microbiome on neuro-autoimmune demyelinating diseases
Abolfazli, P., Nchama, C. N. A., & Lucke-Wold, B. P. (2024) · Academia Biology · doi:10.20935/acadbiol7397 · Cited by 1
Influence of gut microbiota on axonal cells of the brain
Suresh, G., Srivastava, S., & Singh, A. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-29932-2.00004-9 · Cited by 1
Chasov, V. V., Mukhametshin, S. A., Valiullina, A., Skibo, Y. V., Zhumabekova, M., Zharlyganova, D., Keyer, V. V., Kydyrbayeva, A., Shustov, A. V., & Bulatov, E. (2026) · Current Issues in Molecular Biology · doi:10.3390/cimb48090958
“At the same time, greater gut microbiota diversity and the abundance of specific butyrate-producing bacteria were found to be associated with more favorable and safer responses to CAR-T therapy in clinical studies [159,160].”
Metadata
- Authors
- Li, K., Wei, S., Hu, L., Yin, X., Mai, Y., Jiang, C., Peng, X., Cao, X., Huang, Z., Zhou, H., Ma, G., Liu, Z., Li, H., & Zhao, B.
- Affiliations
- Guangdong Medical College (CN)
- University College London (GB)
- Corresponding author
- Liu, Zhou
- Li, Huiliang
- Zhao, Bin
- ORCID
- Venue
- Mediators of Inflammation
- Publisher
- Wiley
- Published
- 2020-08-05
- Volume
- 2020
- Pages
- 1-13
- ISSN
- 0962-9351 (ISSN-L)
- 1466-1861
- PMC
- PMC7426773
- OpenAlex
- W3047080278
- Semantic Scholar
- b6c42028598fcd596386f6e4810382a0f19b46f5
- Cited by
- 92
- References
- 66
- Citations by year
- 2026: 3 · 2025: 15 · 2024: 17 · 2023: 23 · 2022: 15 · 2021: 18 · 2020: 1
- FWCI
- 9.37
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Mediators of Inflammation (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- Affiliated Hospital of GMU (LCYJ2018A003, BJ201612, BJ201515, M2016037, 20182074, A2020282, 2018A01021, 2019KTSCX045, 2020A1515011284, 81400986)
- GMU (LCYJ2018A003, BJ201612, BJ201515, M2016037, 20182074, A2020282, 2018A01021, 2019KTSCX045, 2020A1515011284, 81400986)
- Traditional Chinese Medicine Bureau of Guangdong Province (LCYJ2018A003, BJ201612, BJ201515, M2016037, 20182074, A2020282, 2018A01021, 2019KTSCX045, 2020A1515011284, 81400986)
- Medical Scientific Research Foundation of Guangdong Province (LCYJ2018A003, BJ201612, BJ201515, M2016037, 20182074, A2020282, 2018A01021, 2019KTSCX045, 2020A1515011284, 81400986)
- Science and Technology Planning Project of Zhanjiang (LCYJ2018A003, BJ201612, BJ201515, M2016037, 20182074, A2020282, 2018A01021, 2019KTSCX045, 2020A1515011284, 81400986)
- Ordinary Colleges and Universities in Guangdong (LCYJ2018A003, BJ201612, BJ201515, M2016037, 20182074, A2020282, 2018A01021, 2019KTSCX045, 2020A1515011284, 81400986)
- Natural Science Foundation of Guangdong Province (LCYJ2018A003, BJ201612, BJ201515, M2016037, 20182074, A2020282, 2018A01021, 2019KTSCX045, 2020A1515011284, 81400986)
- National Natural Science Foundation of China (LCYJ2018A003, BJ201612, BJ201515, M2016037, 20182074, A2020282, 2018A01021, 2019KTSCX045, 2020A1515011284, 81400986)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Gastroenterology › Inflammatory Bowel Disease
- Keywords
- fecal microbiota transplantation, multiple sclerosis, experimental autoimmune encephalomyelitis, gut dysbiosis, microglial activation, astrocyte activation, blood-brain barrier, myelin, axons, neuroprotection, microbiota-based therapy
- MeSH terms
- Gastrointestinal Microbiome, Fecal Microbiota Transplantation, Animals, Axons, Blood-Brain Barrier, Disease Models, Animal, Feces, Female, Fluorescent Antibody Technique, Mice, Inbred C57BL, Multiple Sclerosis, Myelin Sheath, RNA, Ribosomal, 16S, Blotting, Western, Microscopy, Electron, Transmission, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.